These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37952507)

  • 41. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
    Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
    Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Podoplanin as an Attractive Target of CAR T Cell Therapy.
    Waseda M; Kaneko S
    Cells; 2020 Aug; 9(9):. PubMed ID: 32858947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of CD44v6, p63, podoplanin and MMP-9 in oral squamous cell carcinomas.
    Monteiro LS; Delgado ML; Ricardo S; do Amaral B; Salazar F; Pacheco JJ; Lopes CA; Bousbaa H; Warnakulasuryia S
    Oral Dis; 2016 May; 22(4):303-12. PubMed ID: 26788715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunohistochemical Expression of Podoplanin in Clinical Variants of Oral Leukoplakia and Its Correlation With Epithelial Dysplasia.
    D'souza B; Nayak R; Kotrashetti VS
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):132-139. PubMed ID: 27153448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.
    Srivastava G; Matta A; Fu G; Somasundaram RT; Datti A; Walfish PG; Ralhan R
    Mol Oncol; 2015 Oct; 9(8):1720-35. PubMed ID: 26115765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations.
    Kreppel M; Scheer M; Drebber U; Ritter L; Zöller JE
    Virchows Arch; 2010 May; 456(5):473-82. PubMed ID: 20393745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Podoplanin in the development and progression of oral cavity cancer: a preliminary study.
    Bartuli FN; Luciani F; Caddeo F; Compagni S; Piva P; Ottria L; Arcuri C
    Oral Implantol (Rome); 2012 Apr; 5(2-3):33-41. PubMed ID: 23285404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
    Kaneko MK; Kunita A; Abe S; Tsujimoto Y; Fukayama M; Goto K; Sawa Y; Nishioka Y; Kato Y
    Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of podoplanin and prognosis in oropharyngeal cancer.
    Preuss SF; Anagiotos A; Seuthe IM; Drebber U; Wedemeyer I; Kreppel M; Semrau R; Eslick GD; Klussmann JP; Huebbers CU
    Eur Arch Otorhinolaryngol; 2015 Jul; 272(7):1749-54. PubMed ID: 24880471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas.
    Funayama A; Cheng J; Maruyama S; Yamazaki M; Kobayashi T; Syafriadi M; Kundu S; Shingaki S; Saito C; Saku T
    Pathobiology; 2011; 78(3):171-80. PubMed ID: 21613804
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer.
    Alhazzazi TY; Kamarajan P; Joo N; Huang JY; Verdin E; D'Silva NJ; Kapila YL
    Cancer; 2011 Apr; 117(8):1670-8. PubMed ID: 21472714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
    Chung YL; Lee MY; Pui NN
    Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lymphangiogenesis and Lymph Node Metastasis in Oral Squamous Cell Carcinoma.
    Arimoto S; Hasegawa T; Takeda D; Saito I; Amano R; Akashi M; Komori T
    Anticancer Res; 2018 Nov; 38(11):6157-6162. PubMed ID: 30396932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach.
    Ribeiro FA; Noguti J; Oshima CT; Ribeiro DA
    Anticancer Res; 2014 Apr; 34(4):1547-52. PubMed ID: 24692681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p73 induction by Abrus agglutinin facilitates Snail ubiquitination to inhibit epithelial to mesenchymal transition in oral cancer.
    Sinha N; Meher BR; Naik PP; Panda PK; Mukhapadhyay S; Maiti TK; Bhutia SK
    Phytomedicine; 2019 Mar; 55():179-190. PubMed ID: 30668428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.
    Nagai K; Nakahata S; Shimosaki S; Tamura T; Kondo Y; Baba T; Taki T; Taniwaki M; Kurosawa G; Sudo Y; Okada S; Sakoda S; Morishita K
    Cancer Med; 2014 Aug; 3(4):1085-99. PubMed ID: 24890018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin.
    Yamada S; Ogasawara S; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):72-76. PubMed ID: 28387591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma.
    Chalise L; Kato A; Ohno M; Maeda S; Yamamichi A; Kuramitsu S; Shiina S; Takahashi H; Ozone S; Yamaguchi J; Kato Y; Rockenbach Y; Natsume A; Todo T
    Mol Ther Oncolytics; 2022 Sep; 26():265-274. PubMed ID: 35991754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.